University Hospital of Patras
Pátrai, Achaia, 26504, Greece
NCT Number: NCT04911218
Transradial approach has become the default arterial access for coronary angiography (CAG) and percutaneous coronary intervention (PCI), mainly due to lower incidence of bleeding compared to transfemoral access.1 However, TRA is not deprived of local access site complications such as radial artery occlusion (RAO), occurring in approximately 5.2% of patients, compartment syndrome, pseudoaneurysm, hematoma, and arteriovenous fistula. Recently, a novel approach has been proposed, the access through the distal radial artery (distal transradial access, dTRA), located in the anatomical snuffbox. Initial studies regarding the dRA have shown feasibility and benefits, including shorter hemostasis time, fewer local access site complications and potentially lower incidence of RAO.
GlideSheath Slender is a novel sheath which has a hydrophilic coating and is made of a thinner material than traditional sheaths. As a result, the external diameter of the 5 Fr GlideSheath Slender sheath is 1 Fr lower compared with conventional arterial sheaths.
The purpose of the present study was to investigate whether the use of the Slender sheath affects the time of hemostasis, sheath insertion time, crossover rate to conventional radial access, pain associated with the procedure and incidence of local access site complications (RAO, distal radial artery occlusion, fistula, hematoma) in patients undergoing diagnostic angiography through the distal radial artery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Pátrai, Achaia, 26504, Greece
Patients fulfilling the enrollment criteria will be randomized 1:1 to GlideSheath Slender versus conventional 5Fr arterial sheath for access through the distal radial artery (dTRA). In case an interventional procedure is required then the initial sheath will be exchanged to a larger sheath according to the circumstances of the case and the patient will not be included in the analysis.
For randomized patients sheath insertion time, necessity for crossover to conventional radial access, pain associated with the procedure (visual pain scale) and occurrence of hematoma will be recorded. Follow-up ultrasound 7-10 days after the procedure for detection of RAO, distal radial artery occlusion and fistula formation will be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
Time frame: At 30 minutes after sheath removal
Time frame: During the procedure
Time frame: During the procedure
0-10, 0: no pain, 10: worst pain possible
Time frame: Up to 24 hours after hemostatic device removal
Time frame: 7-10 days after the coronary angiography
Time frame: 7-10 days after the coronary angiography
Time frame: 7-10 days after the coronary angiography
Time frame: 7-10 days after the coronary angiography
University Hospital of Patras
Other
Randomized Comparison of GlideSheath Slender® Versus Conventional 5Fr Arterial Sheath in Coronary Angiography Through the Distal Radial Artery (Anatomical Snuffbox)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02888431
Arterial Access, Central Venous Catheter
Columbus, Ohio, United States
View Trial DetailsNCT01996553
Arterial Occlusive Diseases, Cardiovascular Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06890312
Anticoagulation, Arterial Occlusive Diseases
Strasbourg, Bas-Rhin, France
View Trial DetailsNCT07621185
Arterial Occlusive Diseases, Cardiac Catheterization
Barcelona, Spain
View Trial Details